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1. Introduction 
Cartilage growth-promoting substances are known 
either as somatomedins (SM), which reflects their 
dependance on GH [ 11, or as insulin-like growth 
factors (IGF), because of the structural homologies 
with insulin of IGF I and II which are, to date, the 
only two SM to have been totally identified [2,3]. SM 
or IGF have been shown to circulate in the blood 
transported by a specific carrier protein [4,5]. Fol- 
lowing the pioneering work of McConaghey [6], the 
liver has been considered as the primary source of 
these growth factors. Using an organ culture technique, 
we have shown that both the IGF and their carrier(s) 
are produced by the liver [7-91 (reviews [9-l 11). 
In view of the increasing number of gastrointestinal 
and pancreatic peptides that are also found in the 
brain [ 12-151 and the fact that certain growth 
promoting factors (such as fibroblast growth factor) 
have been extracted from the pituitary gland and/or 
brain [16-191, we have considered it interesting to 
apply our organ culture technique to these tissues and 
determine whether they produce IGF. Here, we report 
the first evidence that in the rat the pituitary gland 
and various brain tissues (hypothalamus, cerebral 
cortex, cerebellum) maintained in organ culture, 
produce IGF and their carrier protein(s). 
2. Materials and methods 
2.1 Organ culture 
The technique used was the same as that employed 
in [7] for liver culture. Male Sprague Dawley rats 
(100-120 g) were decapitated and the organs quickly 
excised, sliced and pooled before distribution into 
178 
culture dishes containing 2 ml McCoy’s 5a medium 
(Eurobio) without serum. The quantities of tissue/ 
dish were the following: 4 hemi-anterior pituitary 
lobes; 2 neuro-intermediate lobes; 4 hemi-hypo- 
thalamus; 8 cerebral cortex or cerebellum explants 
(15-25 mg each). For each tissue, 6 dishes were 
routinely prepared/experimental condition. After 
24 h culture, the medium was discarded and replaced, 
then the culture continued a further 3 days. The 
media from each set of experimental conditions were 
then pooled and centrifuged (10 min, 3000 X g). An 
aliquot of the supernatant was put aside for the total 
protein assay [20]. The remainder was filtered on 
disposable Sephadex G-25 columns (Pharmacia) in 
0.03 M NHJICOa, then the void volume material was 
lyophilized as in [7] and used for subsequent studies 
(sections 2.2 and 2.5). 
2.2. Extraction of IGF and their carrier from the 
culture media 
Lyophilized material corresponding to 5- 10 ml 
culture medium was gel filtered on 1.5 X 30 cm 
Ultrogel AcA54 (IBF) columns in 1 M CHsCOOH, 
0.15 M NaCI. The fractions containing the IGF and 
the carrier were pooled separately, lyophilized and, 
before assaying, filtered on Sephadex G-25 disposable 
columns equilibrated with 0.1 M phosphate buffer. 
The material used for the assays was that eluted in 
the void volume (sections 2.3,2.4). 
2.3. Competitive protein-binding assay for IGF 
Here the carrier protein extracted from rat liver 
culture media was used, which has an elective affinity 
for SM or IGF (no cross-reaction with other polypep- 
tides including insulin and proinsulin) [9,2 11. The 
ligand was NSILA-S (non-suppressible insulin-like 
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activity soluble, a gift from Dr Zapf, Zurich). The 
partially purified preparation used as standard 
(4.5 mU/mg insulin-like activity) was an approximately 
equimolar mixture of the 2 IGF. The preparation 
used as tracer contained mainly IGF I. 
The total incubation volume was 0.4 ml 0.1 M 
phosphate buffer, each assay tube containing -3000 
cpm 1251-labelled NSILA-S and sufficient carrier (cor- 
responding to 0.1-0.2 ml original liver culture medium) 
to obtain -25% binding in the absence of unlabelled 
NSILA-S (B, samples). Each sample was assayed in 
triplicate t 1 control (no carrier). After 24 h incuba- 
tion, ‘free’ and ‘bound’ IGF were separated with 
charcoal. Results are expressed in serum units of IGF 
compared with a pool of normal adult male rat serum 
arbitrarily assigned a value of 1 serum unit IGF/ml. 
2.4. Radio&and assay for the IGF cam’er protein 
With this assay, the relative IGF carrier concentra- 
tion in an unknown sample was assessed in terms of 
its binding at different concentrations to ‘251-labelled 
NSILA-S [22]. The reference curve was obtained with 
a carrier preparation extracted from a pool of normal 
adult male rat serum arbitrarily assigned a value of 
1 serum unit carrier/ml. The incubation and separation 
were identical to those used for the competitive 
protein-binding assay (section 2.3). Results are 
expressed in serum units of carrier. 
2 5. Gel filtration studies of the [IGF-cam’er] 
complex 
Lyophilized samples (section 2.1) were incubated 
with ‘2sI-labelled NSILA-S in TNE buffer (20 mM 
Tris-HCl (pH 7.4) 150 mM NaCl, 1 mM EDTA, 
0.5 mM PMSF (phenylmethylsulphonylfluoride, 
Serva)) then chromatographed at 4°C on Ultrogel 
AcA44 equilibrated with the same buffer, using a 
1.5 X 90 cm column pumped at a flow rate of 11 ml/h. 
The calibration curve was established with various 
proteins (Sigma) (see fig.4). For each run, SV 40 
virus [3H]DNA (100 &i/mg, gift from J. L. Mandel 
and K. Dott, Strasbourg) and “‘1 were used to deter- 
mine V, (void volume) and Vt (total volume accessible 
to the solvent), respectively. 
3. Results and discussion 
IGF-like substances were found to be present in 
the culture media of all the rat brain tissues studied, 
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Fig.1. Competition curves obtained with IGF-like substances 
extracted from rat pituitary gland and hypothalamus culture 
media in the competitive protein-binding assay for IGF (A, 
anterior lobe; N, neuro-intermediate lobe; H, hypothalamus). 
The binding protein employed for the assay was the specific 
IGF-carrier protein produced by rat liver in culture [9,23]. 
The ligand used as tracer and standard was a purified NSILA-S 
preparation (see section 2). The values along the abscissa 
represent units of insulin-like activity. 
*The curves for the IGF-like substances extracted from the 
culture media have been drawn in such as way as to facilitate 
comparison with the slope of the reference curve. They are 
therefore to be read along the abscissa on a scale with intervals 
corresponding to a dilution factor of 1 S. The first point on 
the curve corresponds to 0.12 ml original culture medium for 
A; 0.10 ml for N; and 0.14 ml for H 
i.e., the anterior and neurointermediate lobes of the 
pituitary gland, the hypothalamus, cerebral cortex 
and cerebellum (fig.1, table 1). Gel filtration of these 
media in CHsCOOH under the conditions used to 
extract IGF from serum [22] yielded, in the fractions 
in which NSILA-S elutes, substances competing with 
1251-labelled NSILA-S in its binding to the IGF-specific 
liver carrier protein. These substances have displace- 
ment curves parallel to that of NSILA-S (fig. 1). 
IGF carriers were also present in these culture 
media: 
(i) Treatment of these media under the identical 
conditions used to extract the carrier from liver 
culture media (fig.2 legend and [22]) yielded a 
substance with a strong affinity for NSILA-S, 
similar to that of the liver carrier protein, and 
with binding sites saturable by quantities as small 
as -2.0 pU/ml NSILA-S (fig.2). In addition, in 
these competitive binding experiments, neither 
insulin nor proinsulin displaced the 1251-labelled 
NSILA-S despite the fact that they have nearly 
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Fig.2. Competitive binding of 1251-labelled NSILA-S to IGF 
carrier proteins extracted from rat adenohypophysis culture 
media. The IGF carrier preparations were obtained by 
Sephadex G-50 gel filtration in 1 M CH,COOH of culture 
media desalted on Sephadex G-25 and lyophilized. The void 
volume material was collected and stored lyophilized. The 
volume for each test tube corresponded to 0.2 ml original 
culture medium and a total protein concentration of -10 pg/ 
ml. Incubation with NSILA-S and separation were done as 
for the IGF competitive binding assay (see section 2). The 
results are the mean + 1 SEM of 3 expt done with 3 different 
preparations of carrier in which the proportions of bound 
‘zSI-labelled NSILA-S in each B, sample were 23, 38 and 29%, 
respectively. The values on the abscissa re expressed in units 
of insulin-like activity. 
(ii) 
50% homologies with IGF [3]. This suggests that 
the binding material was specific for the IGF. 
Fig.3 shows the titration curves of the IGF 
carrier produced by the pituitary gland and other 
brain tissues, compared with the reference curve 
obtained with the serum carrier. It should be 
noted that for any given experiment these titra- 
tion curves were not always parallel to the 
reference curve (not shown). This is in sharp 
contrast with what we observed for the liver 
carrier protein (in preparation) and suggests 
possible structural differences of molecular 
heterogeneity. 
(iii) Ultrogel AcA44 chromatography at neutral pH 
of the material concentrated from the culture 
media and incubated with ‘251-labelled NSILA-S 
gave two peaks (fig.4). The first, which corre- 
sponds to the [IGF-carrier] complex, as demon- 
strated by experiments using unlabelled NSILA-S 
(in preparation), was asymmetrical with Kd 
-0.2 l-O.52 and a mean Kd extrapolated to 
0.39 + 0.03 (SD) (n = 10). The second peak with 
Fig.3. Titration curves of IGF carrier proteins extracted from 
rat pituitary gland and various brain tissue culture media (A, 
anterior lobe; N, neuro-intermediate lobe; H, hypothalamus; 
CO, cerebral cortex; CE, cerebellum). Increasing concentra- 
tions of the various carriers were studied in the presence of 
‘251-labelled NSILA-S under the same conditions as those for 
the radio&and assay for the IGF carrier proteins (see sec- 
tion 2). The reference curve (R) was obtained with a prepara- 
tion of carriers extracted from a pool of rat serum. The 
abscissa carrier values are expressed in serum units of carrier 
(see section 2). 
*The curves for the carriers extracted from the culture media 
(of which only the linear portion is shown) have been drawn 
in such as way as to facilitate comparison with the slope of 
the reference curve. They are to be read along the abscissa on 
a scale with intervals corresponding to a dilution factor of 1.5. 
The fist point on the curve corresponds to 0.04 ml original 
culture medium for A; 0.19 ml for N; 0.42 ml for H; 0.23 ml 
for CO; and 0.28 ml for CE. 
K, - 0.70 corresponds to free IGF. Prior treat- 
ment of the samples with 1 M CHsCOOH had no 
effect on the elution profile (not shown). The 
heterogeneity of the [IGF-carrier] complex, as 
suggested by the chromatographic profile, was 
confirmed by further experiments involving 
rechromatography and sedimentation of the 
complex (in preparation). 
By way of comparison, fig.4 also shows the elution 
pattern of a liver culture medium chromatographed 
under the same conditions after incubation with r2’I- 
labelled NSILA-S. Here the [IGF-carrier] complex 
also eluted with a mean K, 0.39 f 0.01 (n = 9). The 
peak was however symmetrical and narrow: K, 
-0.32-0.52 (here the minor peak at Kd 0.26 corre- 
sponds to molecules non-specifically bound to rz51- 
labelled NSILA-S) (in preparation). The app. IV, of 
-40 000 and rs of -28 A deduced from the K, of 
0.39 and attributed to the liver [IGF-carrier] com- 
plex ([9], in preparation) are merely given here as an 
indication for the pituitary gland and brain [IGF- 
181 
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carrier] complexes in view of their molecular hetero- 
geneity. 
Table 1 shows the different concentrations of IGF 
and of their carrier in the various culture media. 
February 198 1 
Fig.4. Gel filtration study of pituitary gland and liver IGF 
carriers. Lyophilized samples corresponding toeither 10 ml 
rat pituitary gland culture medium (0.55 mg protein) or 10 ml 
rat liver culture medium (1.2 mg protein) were dissolved in
TNE buffer and incubated overnight with “51-labelled 
NSILA-S at 4”C, mixed with SV 40 [ ‘H]DNA and [?]BSA 
as internal markers and chromatographed atpH 7.4 on AcA44 
Ultrogel (see section 2). Proteins were monitored by A,,, and 
radioactivity measured in a y and a p counter. Arrows indi- 
cate the elution position of the markers: SV 40 [3H]DNA 
(3.3 X 106); unlabelled or [Y]BSA dimer (134 000); and 
monomer (67 000); ovalbumin (43 000); soybean trypsin 
inhibitor (20 100); horse myoglobin (17 200); and cyto- 
chrome c (11 700). Profiles similar to those for the adenohy- 
pophysis where obtained with the culture media of the neuro- 
intermediate lobe, the hypothalamus, cerebral cortex and 
cerebellum. 
Whether these are expressed in terms of the total 
protein concentration or the amount of tissue cultured, 
the anterior and neuro-intermediate pituitary lobes 
were found to have released the largest quantities of 
both IGF and carrier and the cerebral cortex and 
cerebellum, the least. Under the same experimental 
conditions, the liver production/mg tissue was similar 
to that of the two pituitary lobes (in preparation). If: 
(i) The variations in production from one tissue to 
another; 
Table 2 
Effects of cycloheximide 
Culture 
medium 
Cyclo- 
heximide 
&g/ml) 
3H-Labelled trichloroacetic 
acid-precipitable material 
@pm/ml) (% Inhib.) 
IGF 
mu/ml 
(serum units) 
% Inhi- 
bition 
Carrier 
mu/ml 
(serum units) 
% Inhi- 
bition 
Anterior lobe 0 
of pituitary 100 
Neurointer- 0 
mediate lobe 100 
Hypothalamus 0 
100 
Cerebral cortex 0 
100 
Cerebellum 0 
100 
815 740 2.77 33 
3140 >99 1.17 58 1.19 94 
36 340 1.14 5 
300 >99 1.05 8 1.85 63 
5280 0.99 2.5 
115 98 <0.44 >56 2.15 14 
8320 1.29 3.5 
835 90 0.64 50 2.42 31 
4690 1.32 3.5 
990 80 0.87 34 2.8 20 
Rat pituitary gland and brain explants were cultured in 12 dishes for each organ, half with and half without cycloheximide (Sigma). 
After 24 h the culture medium was replaced by fresh medium with 4 /.&i/ml [‘Hlleucine (110 Ci/mmol NEN) with or without 
cycloheximide. The culture was continued a further 3 days and the media for each set of experimental conditions then collected 
and pooled separately. [“H]Leucine incorporation into trichloroacetic acid-precipitable material [7] was determined in 100 ~1 
aliquots of culture medium. Values are the mean of 5 measurements corrected by subtraction of the control value (culture medium 
with 13H]leucine, without explants) of 450 dpm/ml. IGF and carrier were assayed after extraction and their concentrations 
expressed in serum units (see section 2). Similar results were obtained in a second experiment 
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(ii) The predominant production of carrier in all indicating a possible action for these peptides as 
tissues; and neuroregulators [23] and brain growth factors [24,25]. 
(iii) The relative concentrations of IGF or carrier/total 
amount of protein as compared with those in 
serum, are taken into account, any notion of a 
simple mechanical release of material formerly 
bound to the tissues into the culture medium 
would seem highly unlikely. Moreover, this possi- 
bility would be minimized by the change of 
medium after 24 h culture. 
Table 2 shows the effects of cycloheximide added 
to the culture medium. It appears that, under the 
influence of the drug: 
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6) 
(ii) 
The incorporation of [3H]leucine into the pro- 
teins released in the media was strongly inhibited 
in all the tissues; 
The IGF and/or carrier concentrations in the cul- 
ture media decreased in every tissue cultured (the 
strongest inhibition occuring in the adenohypo- 
physis culture). 
The results suggest a synthesis of IGF and carrier in 
the pituitary gland and the brain. 
4. Concluding remarks 
The anterior and neuro-intermediate lobes of the 
pituitary gland, the hypothalamus, cerebral cortex 
and cerebellum of the rat, maintained in organ cul- 
ture, release both IGF and their carrier protein. Pro- 
duction is highest in the pituitary lobes and lowest in 
the cerebral cortex and cerebellum, although it is 
possible that the latter was due to inadequate culture 
conditions for these tissues. 
The nature of the brain IGF remains unknown as 
the rat liver carrier protein used to identify them 
recognizes IGF I, IGF II, SM-A and MSA [21]. The 
brain tissue IGF carriers appear to be different from 
that produced by the liver and the relationships 
between these various carriers and that present in the 
serum remain to be clarified. 
The control of the synthesis of the brain IGF and 
their function have yet to be determined. It is unlikely 
that they play a physiological role in somatic growth 
(computations from our results suggest hat the total 
production by the brain would correspond to <5% 
of that by the liver ‘in vitro’). Nevertheless, it can be 
imagined that the IGF synthesized by the brain and 
pituitary gland have a local role, as suggested by the 
detection of somatomedin receptors in the brain 
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